Objective To investigate the effect of prednison combined with cytoxan (CTX) on the efficacy and renal function pa‐rameters in patients with immunoglobulin A (IgA) nephropathy .Methods A total of 86 cases with IgA nephropathy patients were divided into observation group(n=43) and control group(n= 43) from June 2013 to June 2015 .The control group groups were treated with prednison ,while the observation groups were given the treatment of prednison combined with CTX ,and both groups were continuously treated for 12 weeks .The efficacy and renal function indexes of two groups were compared .Results The total effective rates of observation group and control group were 97 .67% and 79 .07% ,respectively ,and the difference was statistically significance (P<0 .05) .The levels of treatment urea nitrogen (BUN) ,serum creatinine (Scr) ,24 h urine protein of observation groups were (4 .33 ± 1 .24) mmol/L ,(85 .36 ± 5 .85) mol/L and (1 .89 ± 0 .24) g after treatment ,which were all significantly lower than that of the control group [(6 .32 ± 2 .02)mmol/L ,(158 .25 ± 8 .36) mol/L and (4 .22 ± 0 .32)g](P<0 .05) .Meanwhile ,endog‐enous creatinine clearance rate (Ccr) (85 .98 ± 14 .02) was significantly higher than that of the control group (68 .23 ± 12 .02) (P<0 .05) .The levels of renal vascular index ,blood pellets index ,tubular‐interstitial index ,crescent index of observation group after treatment were (2 .12 ± 0 .96) points ,(2 .12 ± 0 .88) points ,(2 .02 ± 0 .85) points and 0 .22 ± 0 .08 respectively ,which were signifi‐cantly lower than that of the control group [(3 .02 ± 0 .85) points ,(3 .85 ± 1 .22) points ,(3 .12 ± 0 .96) points and 0 .48 ± 0 .10] (P<0 .05) .Adverse reaction rate between the two groups were not statistically significant (P>0 .05) .Conclusion Prednison com‐bined with CTX can improve clinical efficacy of patients with IgA nephropathy ,as well as improve renal function ,which has lower rate of adverse reactions .In addition ,it is a safe and effective method ,which is worthy of clinical application .

目的：观察增血汤联合红细胞生成素（EPO ）治疗维持性血透肾性贫血患者的疗效。方法：120例患者随机分为治疗组和对照组，治疗组使用增血汤联合EPO 进行治疗，对照组使用EPO治疗，观察总体疗效情况及 Hb、Hct值变化情况。结果：治疗组治愈率为93．8％，对照组治愈率为77．5％，两组经统计学比较有明显差异（P＜0．05）；两组治疗后 Hb及 HCT 值和治疗前比较有显著提高（P＜0．05）；治疗组Hb值经4周治疗后有明显提高，和治疗前比较有显著差异（P＜0．05）；治疗组经8周治疗后Hb及HCT值和对照组比较有显著差异（P＜0．05）。结论：增血汤联合EPO治疗维持性血透肾性贫血具有较好疗效，值得应用。

目的：研究肾康注射液对维持性血液透析患者氧化应激及微炎症状态的影响。方法：选取我院肾内科行维持性血液透析的患者80例，按照随机数字表法分为治疗组和对照组各40例，对照组予调节血压、改善贫血等常规治疗，治疗组在对照组治疗基础上加用肾康注射液，比较两组患者治疗前后氧化应激水平、微炎症状态及药物不良反应发生情况。结果：对照组治疗前后MDA、SOD、A-TOC、CRP、IL-6、TNF-α水平均无明显变化（P＞0.05）；治疗组治疗后MDA、CRP、IL-6、TNF-α较治疗前明显降低，而SOD、T-AOC明显升高（P＜0.05）；和对照组比较，治疗组治疗后MDA、SOD、T-AOC、CRP、IL-6、TNF-α改善更加明显，差异有统计学意义（P＜0.05）；两组患者治疗期间不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：肾康注射液可降低维持性血液透析患者的微炎症反应水平，促进氧化和抗氧化之间的平衡，临床疗效确切，安全性高。

<正>笔者所在科自2005年对激素停药后复发或每天需要泼尼松剂量15mg以上的难治性自身免疫性溶血性贫血(AIHA)患者,采用来氟米特(LFM)联合小剂量环孢菌素(CsA)方案治疗。现将治疗效果总结报告如下。

Objective To strengthen the screening and diagnosis of anaemic etiopathogenisis ,and preventing misdiagnosis and mistreatment.Methods Bone marrow,fecal occult blood,blood urea nitrogen were set up as a barometer for the etiological. Results of 268 cases of severe anemia patients,16 cases were confirmed as intestinal cancer. Conclusion Severe anemia is an early clinical manifestation of the small intestine cancer. Screening and diagnosis of anaemic etiopathogenisis is the key to patients with anaemic.

骨髓增生异常综合征(myelodysplastic syndromes,MDS)是一组起源于造血干细胞的获得性克隆性疾病.MDS的治疗方案虽然很多,但由于疗效有限,目前尚无共识方案.近年来笔者采用小剂量马法兰联合沙利度胺治疗老年MDS中的RAEB-I及RAEB-II亚型患者10例,取得初步疗效,报道如下.